Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282252 | 0.83 | NOS1 (0.43) | NOS1NOS2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL3282110 | 0.81 | TAAR1 (0.52) | NOS1NOS2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL8866594 | 0.81 | CYP1A2 (0.51) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL9322352 | 0.80 | CYP1A2 (0.50) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3924798 | 0.79 | TACR1 (0.44) | NOS1NOS2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL3283174 | 0.76 | ACHE (0.48) | NOS1NOS2 | |
| SCHEMBL12894954 | 0.76 | SLC6A2 (0.57) | CYP2D6SLC6A2SLC6A4SLC6A3FDPS | |
| SCHEMBL290633 | 0.76 | SLC6A2 (0.57) | CYP2D6SLC6A2SLC6A4SLC6A3FDPS | |
| SCHEMBL29669201 | 0.76 | SLC6A2 (0.57) | CYP2D6SLC6A2SLC6A4SLC6A3FDPS | |
| SCHEMBL22197081 | 0.75 | KCNA5 (0.43) | CYP3A4CYP2D6KDM4EVNN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018364-B1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-7709507-B2 | Therapeutic fluoroethyl ureas | ALLERGAN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | SLC14A1, MAPT, UTS2R | NOS1 3412/4885NOS2 3148/4885CYP3A4 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.